Discover a new way to find and share stories you'll love… Learn about Reading Desk

All Blogs / Industries / Medical / Pharmaceutical / Popular


Thiola, Retrophin, Martin Shkrell, Reddit, and More

Well, it was not a dull evening around the In the Pipeline headquarters last night. I submitted a link to Reddit for my post yesterday about Retrophin and Thiola, and that blew up onto that site's front page. The Corante server melted under the impact, which isn't too surprising, since it's struggling at the best of times. Show More Summary

The Pharma Social Media Pioneering Era is Over! Long Live the Pharma Mobile App Pioneer!

Today I will chairing CBI's Social Media Compliance Strategies and Benchmarking Summit in Philadelphia. In my opening comments I declared that the pharma social media pioneer era is over. Here's a draft of what I said: Welcome fellow...Show More Summary

The Most Unconscionable Drug Price Hike I Have Yet Seen

There's a drug called Thiola (tiopronin) that most people have never heard of. It's on my list of "smaller than aspirin" drugs, and I'd never heard of it until I put that one together. But thanks to a little company called Retrophin,...Show More Summary

Inside Express Scripts’ Narrow Network Strategy—and How It Beat Walgreens

Last month, AIS Health held a fascinating webinar: Health Plan/Employer Strategies for Implementing Narrow Pharmacy Networks. (A CD and on-demand recording are available for purchase.) The webinar featured a Milliman consultant, a Medicaid...Show More Summary

Clinical Trial Fraud

Bizarre news from Evotec - see what you make of this press release: Evotec AG was informed that US company Hyperion Therapeutics, Inc. ("Hyperion") is terminating the development of DiaPep277(R) for newly diagnosed Type 1 diabetes. In...Show More Summary

Grinding Up Your Reactions

I'd seen various solventless reactions between solid-phase components over the years, but never tried one until now. And I have to say, I'm surprised and impressed. I can't quite say which literature reference I'm following, unfortunately,...Show More Summary

Peer Review, Up Close and Personal

Retraction Watch has a rare look behind the peer review curtain in the (now notorious) case of the STAP stem cell controversy. This was the publication that claimed that stem-like cells could be produced by simple acid treatment, and this work has since been shown to be fraudulent. Show More Summary

Google's Calico Moves Into Reality

Google's Calico venture, the company's out-there move into anti-aging therapy, has made the news by signing a deal with AbbVie (the company most of us will probably go on thinking of as Abbott). That moves them into the real world for sure, from the perspective of the rest of the drug industry, so it's worth taking another look at them. Show More Summary

CMS Forecast: Big Drug Spending Growth, But Hospitals and Doctors Will Still Capture Most Healthcare Spending

Last week, the Centers for Medicare & Medicaid Services (CMS) released its latest forecasts for national health expenditures. The forecast is summarized in a new Health Affairs article: National Health Expenditure Projections, 2013?23:...Show More Summary

Which way now for the Cancer Drug Fund? by Andrew Jack

BMJ 2014; 349 doi: http://dx.doi.org/10.1136/bmj.g5524 (Published 09 September 2014)Cite this as: BMJ 2014;349:g5524Andrew Jack, deputy editor, analysis, Financial Times, London, UKandrew.jack@ft.comThe government has extended the Cancer Drug Fund for a further two years and increased its budget. Show More Summary

Reactive Groups: Still Not So Reactive

Just how reactive are chemical functional groups in vivo? That question has been approached by several groups in chemical biology, notably the Cravatt group at Scripps. One particular paper from them that I've always come back to is this one, where they profiled several small electrophiles across living cells to see what they might pick up. Show More Summary

NORD’s Rare Diseases and Orphan Products Breakthrough Summit

NORD’s Rare Diseases and Orphan Products Breakthrough SummitOctober 21-22, 2014 | Alexandria, VABrought to you by NORD; Powered by CBIwww.cbinet.com/NORD NORD’s Rare Diseases and Orphan Products Breakthrough Summit is the largest and most meaningful multistakeholder event of its kind. Show More Summary

Weekly Roundup 9.5.14

After a surprisingly mild August, September begins with summer in full force – heat, humidity and a mosquito rally that is immensely annoying.  Forecasts however predict that we only have one more day of this and then a break to … Continue reading ?

FDA Says Men Who Receive Drugs for "Low-T" Have 30% Increased Risk of Major Adverse Cardiovascular Events

As I reported back in February this year, Public Citizen urged the FDA to immediately add a black box warning about the increased risks of heart attacks and other cardiovascular dangers to the product labels of all testosterone-containing drugs available in the U.S. Show More Summary

A VC Firm Touts Its Successes - And Its Failures

Here's what sounds like a good idea from VC firm Index Ventures, from the latest issue of BioCentury (same one I referenced the other day). Like many others in the biopharma venture capital world, they're trying to run the "killer experiment" as soon as possible, to see which ideas for new companies look solid. Show More Summary

Will Kids Abandon This Diabetes Mobile Game App from Sanofi Before Reaching Level 2?

Mission T1D - Sanofi Diabetes is on a Mission to Support Children with Type 1 Diabetes through Gaming

Are Your Compounds Ugly? Do You Know?

A reader sends along this paper, on some small molecules targeting the C2 domain of coagulation factor VIII. It illustrates some points that have come up around here over the years, that's for sure. The target is not a particularly easy one: a hit would have to block the interaction of that protein domain with a membrane surface. Show More Summary

A Question: Monoclonal Antibodies in the Clinic

A reader sends along this query, and since I've never worked around monoclonal antibodies, I thought I'd ask the crowd: how much of a read on safety do you get with a mAb in Phase I? How much Phase I work would one feel necessary to feel safe going on to Phase II, from a tox/safety standpoint? Any thoughts are welcome. Show More Summary

Copyright © 2011 Regator, LLC